HIV Pipeline
← Отчётные звонки
01
02
03
04 05 06
Тон
A1 A2 A3
GILD
FY2026 Q1
Повышен
Отчётный звонок Gilead Sciences, Inc.
Вывод Buzzberg
HIV franchise positioned for durable growth with seven potential launches by 2033
Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY).
Вывод Buzzberg HIV franchise positioned for durable growth with seven potential launches by 2033 Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY). Читать полный анализСвернуть анализ
Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY).
- Yes2Go sales: $166M in Q1 (up 72% sequential), full-year 2026 guidance raised to $1B from $800M.
- 2026 total product sales guidance raised by $400M to $30.0-30.4B; non-GAAP EPS is a loss of $1.05-$0.65 due to ~$11.5B in acquired IPR&D charges.
- Acquisition of Arcelix closed April 28th; anito-cel PDUFA is December 2026, with revenue expected to begin early 2027.
HIV Выручка$5BФакт
Выручка$6.96B-12% к/к
YES2GO Выручка166Факт
EPS$2.03+9% к/к
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Demand
Yes2Go guidance raised to blockbuster $1 billion in first full year
HIV Treatment
BicLen FDA decision expected in August under priority review
Показать ещё 3 тезиса
Oncology
Trodelvy first-line metastatic TNBC decisions expected in second half 2026
Cell Therapy
AnitoCell revenue expected to begin in early 2027
Cell Therapy
AnitoCell positioned as foundational multiple myeloma therapy
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| HIV Выручка | $5B | Факт |
| Выручка | $6.96B | -12% к/к |
| YES2GO Выручка | 166 | Факт |
| EPS | $2.03 | +9% к/к |
| Валовая маржа | 79.24% | Факт |
| Операционная маржа | 37.16% | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2026 | $-1.05–$-0.65В соответствии с консенсусом | $-0.85 | Подтверждён |
| ВыручкаHIV | FY2026 | $1BВыше консенсуса | $1B | Повышен |
| Выручка | FY2026 | $30B–$30.4BВ соответствии с консенсусом | $30.2B | Повышен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management repeatedly highlighted execution strength, raised product sales guidance, and framed upcoming decisions and launches as growth catalysts.
все упомянутые компании ниже: 3
Компаниис момента звонка
Партнёры
Партнёры
Dietmar Berger
Gilead's pending acquisition of Oral Medicines includes a licensing deal with Galapagos for gamgertamig, highlighting a deepening partnership.
Доказательства
“we expect to develop in collaboration with Galapagos”
Партнёры
Dietmar Berger
Gilead is shifting its commercial strategy in HIV treatment by actively marketing a new brand (BicLen) that will cannibalize its flagship Biktarvy, aiming to capture patients who would otherwise switch to competitors. — This is a defensive launch to protect market share; while it may cannibalize Biktarvy, it is expected to keep higher-value patients within Gilead's portfolio.
Доказательства
“we continue to target updates from the Phase 3 Island 1 and 2 trials in collaboration with Merck later this quarter.”
Инвестиции
ARCLX
Инвестиции
Daniel O'Day
The completed acquisition is expected to be a major growth driver for Gilead's cell therapy business, with the anito-cel CAR-T targeted for a late-December PDUFA.
Доказательства
“Our acquisition of Arcelix, which closed on April 28th, reflects our conviction in the potential of a needle cell as a differentiated option for patients with multiple myeloma.”
Внешние сигналы
Альфа цепочки поставок · 3с момента звонка
The $1 billion full-year 2026 Yes2Go sales target implies a doubling from the current annualized run rate (Q1: $166M, up 72% sequentially) and likely assumes a very high persistency rate, a key risk if real-world adherence is lower than expected.
Доказательства
“Given the outperformance of Yes2Go in the first quarter and our growing confidence in the trends we're seeing, we're increasing our 2026 Yes2Go guidance to $1 billion, potentially achieving blockbuster status in its first full year.”
Gilead is shifting its commercial strategy in HIV treatment by actively marketing a new brand (BicLen) that will cannibalize its flagship Biktarvy, aiming to capture patients who would otherwise switch to competitors.
Доказательства
“We believe with Biclen, there's an opportunity to play in that switch market, which we haven't had in the past, and move them from Bicarbine, if they're going to switch anyway, to Biclen.”
The company is investing heavily in direct-to-consumer marketing for Yes2Go, which is a significant shift in strategy for a disease where outdated stigma has historically been a barrier to PrEP adoption.
Доказательства
“Our DTC started late February, and what we've been seeing is a huge increase in brand awareness and visibility”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 3. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.